AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6352654 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (3 mg/kg/day)
Number of subjects: 62
Study 29945203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 417
Study 29945203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 417
Study 29945203 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks (ADA)
Number of subjects: 417
Study 29945203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 417
Study 29945203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXEQ4W and IXEQ2W)
Number of subjects: 417
Study 26593858 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) 3 days per week for 16 weeks
Number of subjects: 39
Study 26593858 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 39
Study 24131447 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B phototherapy (3 times a week for 2 weeks)
Number of subjects: 42
Study 24131447 — intervention group
Group type: COMPARATOR
Intervention: Control group (prior pruritus treatment)
Number of subjects: 42
Study 22244829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (AFP < 100 ng/mL, PRETEXT IV, vascular invasion, extra-hepatic intra-abdominal disease, metastases)
Number of subjects: 541
Study 22244829 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-risk group (PRETEXT I/II/III, no other factors)
Number of subjects: 541
Study 22244829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (PRETEXT IV, multifocal tumour, age > 5 years, AFP > 1.2 × 10(6) ng/mL)
Number of subjects: 541
Study 20367555 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 290
Study 20367555 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 290
Study 18791426 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic supportive psychotherapy
Number of subjects: 81
Study 16202678 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis
Number of subjects: 20
Study 16202678 — intervention group
Group type: COMPARATOR
Intervention: Rigid osteotomy healing
Number of subjects: 20
Study 16202678 — intervention group
Group type: COMPARATOR
Intervention: Comparison between distraction osteogenesis and rigid osteotomy
Number of subjects: 20
Study 11856128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 246
Study 11856128 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 246
Study 11856128 — intervention group
Group type: COMPARATOR
Intervention: Control group (acute abdominal pain)
Number of subjects: 246
Study 10432408 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG) supplementation (0.2 g/kg body wt/day) for six months
Number of subjects: 0
Study 10432408 — intervention group
Group type: COMPARATOR
Intervention: Control vehicle (CRF-C)
Number of subjects: 0
Study 7997564 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging at 1.5 T
Number of subjects: 132
Study 7997564 — intervention group
Group type: COMPARATOR
Intervention: MR imaging at 0.5 T
Number of subjects: 132
Study 2331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid gel (buffering capacity 70 meq/10 ml)
Number of subjects: 10
Study 2331951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein pancake
Number of subjects: 10
Study 2331951 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate pancake
Number of subjects: 10
Study 44907 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin
Number of subjects: 28
Study 44907 — intervention group
Group type: EXPERIMENTAL
Intervention: cefaclor
Number of subjects: 28
Study 30550821 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-TREAT
Number of subjects: 5
Study 28241420 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54 mg/day)
Number of subjects: 121
Study 28241420 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg) and vitamin D3 (800 IU) - placebo
Number of subjects: 121
Study 25788034 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 3
Study 25788034 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 3
Study 25788034 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 3
Study 23962782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-accelerometry (monthly 6MWTs)
Number of subjects: 155
Study 21241726 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 42
Study 21241726 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 42
Study 19903804 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA screening with cytology triage
Number of subjects: 108425
Study 19903804 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology screening
Number of subjects: 108425
Study 17308315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking for 45 min three times a week for 12 weeks
Number of subjects: 21
Study 17308315 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 15114908 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcomes with early warning signals
Number of subjects: 83
Study 15114908 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcomes without early warning signals
Number of subjects: 83
Study 15114908 — intervention group
Group type: COMPARATOR
Intervention: Positive outcomes
Number of subjects: 83
Study 11299430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC)
Number of subjects: 64
Study 11299430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11084116 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 42
Study 11084116 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 42
Study 11084116 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular pacing
Number of subjects: 42
Study 11084116 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS width shortening
Number of subjects: 42
Study 11084116 — intervention group
Group type: COMPARATOR
Intervention: Intrinsic QRS width
Number of subjects: 42
Study 11084116 — intervention group
Group type: COMPARATOR
Intervention: Intrinsic QRS width comparison between coronary artery disease and dilated cardiomyopathy
Number of subjects: 42
Study 11084116 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 42
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smokers
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: < 5 cigarettes per day
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-14 cigarettes per day
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-24 cigarettes per day
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 25 cigarettes per day
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers < 3 years since stopping smoking
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers 3-6 years since stopping smoking
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers 7-15 years since stopping smoking
Number of subjects: 2569
Study 8818604 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers >= 16 years since stopping smoking
Number of subjects: 2569
Study 1602293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg suppository)
Number of subjects: 50
Study 1602293 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine (2 mg suppository)
Number of subjects: 50
Study 1602293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6608203 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6608203 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 0
Study 6608203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31029046 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 (1:1)
Number of subjects: 98
Study 31029046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no probiotics)
Number of subjects: 98
Study 31029046 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 (1:1) in aged Balb/c mice
Number of subjects: 98
Study 31029046 — intervention group
Group type: COMPARATOR
Intervention: Control mice (placebo)
Number of subjects: 98
Study 28338531 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 6117
Study 28338531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives
Number of subjects: 6117
Study 27353769 — intervention group
Group type: EXPERIMENTAL
Intervention: HAnOX-M (HA 31mg/2ml + mannitol 70mg/2ml)
Number of subjects: 205
Study 27353769 — intervention group
Group type: COMPARATOR
Intervention: Bio-HA (HA 20mg/2ml)
Number of subjects: 205
Study 27353769 — intervention group
Group type: EXPERIMENTAL
Intervention: HAnOX-M
Number of subjects: 205
Study 27353769 — intervention group
Group type: COMPARATOR
Intervention: Bio-HA
Number of subjects: 205
Study 24691217 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week physiotherapy programme with repetitive exercises of cueing and movement strategies
Number of subjects: 22
Study 24691217 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 22
Study 22943847 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture Capsulorrhaphy (SC)
Number of subjects: 12
Study 22943847 — intervention group
Group type: COMPARATOR
Intervention: Suture Anchor Capsulorrhaphy (SAC)
Number of subjects: 12
Study 20152022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing chlorine dioxide (ClO2)
Number of subjects: 15
Study 20152022 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (without ClO2)
Number of subjects: 15
Study 17441414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with carbamylated allergoid (SLIT)
Number of subjects: 56
Study 17441414 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 56
Study 15610945 — intervention group
Group type: EXPERIMENTAL
Intervention: psychotherapy plus mirtazapine
Number of subjects: 60
Study 15610945 — intervention group
Group type: EXPERIMENTAL
Intervention: psychotherapy plus venlafaxine
Number of subjects: 60
Study 15610945 — intervention group
Group type: COMPARATOR
Intervention: psychotherapy (control group)
Number of subjects: 60
Study 11878657 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA5 (size 5 LMA with a 7.0 mm nasal RAE tube)
Number of subjects: 80
Study 11878657 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM (intubating laryngeal mask with an 8.0 mm special reinforced tracheal tube)
Number of subjects: 80
Study 11878657 — intervention group
Group type: COMPARATOR
Intervention: LMA3/4 (size 3 or 4 LMA with a 6.0 mm nasal RAE tracheal tube)
Number of subjects: 80
Study 11878657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patil group (endoscopy mask with a 7.5 mm standard tracheal tube)
Number of subjects: 80
Study 11878657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patil group
Number of subjects: 80
Study 9489271 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cocaine dependence
Number of subjects: 518
Study 9489271 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cocaine, sedative, or alcohol dependence
Number of subjects: 518
Study 7603217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 80
Study 7603217 — intervention group
Group type: COMPARATOR
Intervention: K-Y gel (placebo)
Number of subjects: 80
Study 2085584 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treated catheter
Number of subjects: 86
Study 2085584 — intervention group
Group type: COMPARATOR
Intervention: Untreated control catheter
Number of subjects: 86
Study 31790968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear commitment condition
Number of subjects: 80
Study 31790968 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclear commitment condition
Number of subjects: 80
Study 31111344 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulite™
Number of subjects: 69
Study 31111344 — intervention group
Group type: COMPARATOR
Intervention: Optifast™
Number of subjects: 69
Study 28537354 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS device
Number of subjects: 116
Study 28537354 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS device
Number of subjects: 116
Study 25829377 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (stationary biking) for 6 months
Number of subjects: 81
Study 25829377 — intervention group
Group type: COMPARATOR
Intervention: Life-as-usual (control group)
Number of subjects: 81
Study 22290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dyadic intervention (three-session)
Number of subjects: 484
Study 22290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive dyadic intervention (six-session)
Number of subjects: 484
Study 22290823 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 484
Study 20584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1,050 mg/d of eicosapentaenoic acid (EPA) and 150 mg/d of docosahexaenoic acid (DHA))
Number of subjects: 432
Study 20584525 — intervention group
Group type: COMPARATOR
Intervention: Matched sunflower oil placebo (2% fish oil)
Number of subjects: 432
Study 19861864 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 gm of dates (Rothana and Sukari) ingested on two separate dialysis sessions
Number of subjects: 9
Study 19861864 — intervention group
Group type: COMPARATOR
Intervention: 20 meq of KCl
Number of subjects: 9
Study 19861864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two types of dates
Number of subjects: 9
Study 16903603 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-hot needle therapy
Number of subjects: 600
Study 16903603 — intervention group
Group type: COMPARATOR
Intervention: Filiform needle therapy
Number of subjects: 600
Study 15023569 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin‐1A receptor binding in patients with schizophrenia
Number of subjects: 11
Study 15023569 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (22 age-matched and gender-matched)
Number of subjects: 11
Study 15023569 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serotonin‐1A receptor binding with symptoms
Number of subjects: 11
Study 11207993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 30
Study 11207993 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 30
Study 9220237 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 0
Study 9220237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8193487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (2 mg)
Number of subjects: 176
Study 8193487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (1 mg)
Number of subjects: 176
Study 8193487 — intervention group
Group type: COMPARATOR
Intervention: Comparison of oral vs intramuscular vitamin K1
Number of subjects: 176
Study 3073933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous imipenem (Group 1)
Number of subjects: 35
Study 3073933 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Group 2)
Number of subjects: 35
Study 31099036 — intervention group
Group type: EXPERIMENTAL
Intervention: Biting endurance exercises controlled by biofeedback
Number of subjects: 46
Study 31099036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated laser therapy)
Number of subjects: 46
Study 29072885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary ultrasound (CPUS) examination
Number of subjects: 180
Study 29072885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPUS examination)
Number of subjects: 180
Study 25526373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.1 ng/kg
Number of subjects: 25
Study 25526373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.25 ng/kg
Number of subjects: 25
Study 25526373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.5 ng/kg
Number of subjects: 25
Study 25526373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 1.0 ng/kg
Number of subjects: 25
Study 25526373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 2.0 ng/kg
Number of subjects: 25
Study 25526373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 25
Study 23289919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up intervention focusing on blood pressure and lipid control, tobacco use, and physical activity.
Number of subjects: 200
Study 23289919 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study 21656308 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg IM) and Neostigmine (1 mg IM)
Number of subjects: 10
Study 21656308 — intervention group
Group type: COMPARATOR
Intervention: Secretin (1 U/kg IV)
Number of subjects: 10
Study 18432395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and muscle strength training
Number of subjects: 285
Study 17137514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) using a reciprocating platform at frequencies lower than 20 Hz, 12.6 Hz frequency, 3 cm amplitude, 60 degrees of knee flexion, 3 sessions per week for 8 months
Number of subjects: 28
Study 17137514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 28
Study 17137514 — intervention group
Group type: COMPARATOR
Intervention: Walking group, 55 minutes of walking and 5 minutes of stretching, 3 sessions per week for 8 months
Number of subjects: 28
Study 12765311 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (low or moderate dose administered in two daily doses)
Number of subjects: 0
Study 12765311 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids in conjunction with prednisone
Number of subjects: 0
Study 12765311 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of inhaled corticosteroids
Number of subjects: 0
Study 12765311 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 10872704 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (therapeutic INR 2.8-4.2)
Number of subjects: 3606
Study 10872704 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg Aspirin daily
Number of subjects: 3606
Study 10872704 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg Aspirin daily combined with Warfarin (INR 2.0-2.5)
Number of subjects: 3606
Study 8636903 — intervention group
Group type: EXPERIMENTAL
Intervention: High self‐handicappers who did not practice much
Number of subjects: 0
Study 8636903 — intervention group
Group type: COMPARATOR
Intervention: High self‐handicappers who practiced a lot
Number of subjects: 0
Study 1317928 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat products (3 g or more of soluble fiber)
Number of subjects: 20
Study 1317928 — intervention group
Group type: COMPARATOR
Intervention: Wheat control groups
Number of subjects: 20
Study 6469082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion test
Number of subjects: 0
Study 6469082 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin infusion test with cimetidine (200 mg bolus after one hour)
Number of subjects: 0
Study 30005329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (200 mg)
Number of subjects: 15
Study 30005329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27285466 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg, administered twice daily for 9 doses
Number of subjects: 0
Study 27285466 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 50 mg, administered twice daily for 9 doses
Number of subjects: 0
Study 27285466 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg, administered as a positive control
Number of subjects: 0
Study 27285466 — intervention group
Group type: COMPARATOR
Intervention: Placebo, used as a control
Number of subjects: 0
Study 25646746 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG hydrogel spinal sealant
Number of subjects: 98
Study 25646746 — intervention group
Group type: COMPARATOR
Intervention: Standard of care methods
Number of subjects: 98
Study 23277436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated on CPB (VG)
Number of subjects: 30
Study 23277436 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilated on CPB (NVG)
Number of subjects: 30
Study 21119523 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified porridge flour (rich level of micronutrients)
Number of subjects: 125
Study 21119523 — intervention group
Group type: COMPARATOR
Intervention: Basal level of micronutrients in porridge flour
Number of subjects: 125
Study 21119523 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified food (both groups)
Number of subjects: 125
Study 19042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) in 9 weekly group sessions
Number of subjects: 177